Monoclonal antibodies in cancer therapy.
作者信息
Scott Andrew M, Allison James P, Wolchok Jedd D
机构信息
Ludwig Institute for Cancer Research, Melbourne, Australia.
出版信息
Cancer Immun. 2012;12:14. Epub 2012 May 1.
Abstract
摘要
相似文献
1
Monoclonal antibodies in cancer therapy.癌症治疗中的单克隆抗体。
Cancer Immun. 2012;12:14. Epub 2012 May 1.
2
Therapeutic monoclonal antibodies: introduction.治疗性单克隆抗体：引言
Semin Oncol. 2014 Oct;41(5):556-8. doi: 10.1053/j.seminoncol.2014.09.011. Epub 2014 Sep 28.
3
4
Human tumour-associated antigens: targets for monoclonal antibody-mediated cancer therapy.人类肿瘤相关抗原：单克隆抗体介导的癌症治疗靶点
Cancer Surv. 1985;4(1):271-90.
5
6
"Antibodies in cancer treatment".癌症治疗中的抗体
Crit Rev Oncol Hematol. 2007 Apr;62(1):23-5. doi: 10.1016/j.critrevonc.2007.02.004.
7
Advances in cancer: antibody targeting of cancer--prospects for detection and therapy.癌症进展：癌症的抗体靶向治疗——检测与治疗前景
N J Med. 1987 Mar;84(3):195-8.
8
Meeting highlights: 5th Annual International Congress on Monoclonal Antibodies in Cancer, August 2005, Quebec City, Canada.会议亮点：2005年8月于加拿大魁北克市召开的第五届单克隆抗体治疗癌症国际年会。
Clin Lymphoma Myeloma. 2005 Sep;6(2):71-6. doi: 10.1016/s1557-9190(11)70371-7.
9
[Development and use of anti-epithelial antibodies in solid tumors].[实体瘤中抗上皮抗体的研发与应用]
Internist (Berl). 2001 Jun;42(6):827-34. doi: 10.1007/s001080170125.
10
New solid tumor targets for therapeutic monoclonal antibodies.治疗性单克隆抗体的新型实体瘤靶点。
Expert Opin Ther Targets. 2007 May;11(5):585-8. doi: 10.1517/14728222.11.5.585.
引用本文的文献
1
The impact of immunotherapy on the prognosis of small cell carcinoma of the esophagus: a propensity score-matched analysis of a retrospective study.免疫疗法对食管小细胞癌预后的影响：一项回顾性研究的倾向评分匹配分析
Front Immunol. 2025 Aug 22;16:1634834. doi: 10.3389/fimmu.2025.1634834. eCollection 2025.
2
Emerging trends in synthesis, characterization, and mechanism of action of antibody-drug and antibody-nanoparticle conjugates.抗体-药物和抗体-纳米颗粒缀合物的合成、表征及作用机制的新趋势
Discov Nano. 2025 Aug 18;20(1):139. doi: 10.1186/s11671-025-04303-w.
3
Heterohybridomas producing human immunoglobulin light chains using CD138-selected bone marrow cells.使用CD138筛选的骨髓细胞产生人免疫球蛋白轻链的异种杂交瘤。
Biochem Biophys Rep. 2025 Apr 23;42:102017. doi: 10.1016/j.bbrep.2025.102017. eCollection 2025 Jun.
4
Evaluating the immune effector functions induced by humanized anti-CD99 antibody in eliminating T lymphoblastic leukemia/lymphoma cells.评估人源化抗CD99抗体诱导的免疫效应功能在清除T淋巴母细胞白血病/淋巴瘤细胞中的作用。
Discov Oncol. 2025 Apr 11;16(1):514. doi: 10.1007/s12672-025-02281-0.
5
Revolutionary Cancer Therapy for Personalization and Improved Efficacy: Strategies to Overcome Resistance to Immune Checkpoint Inhibitor Therapy.用于个性化治疗和提高疗效的革命性癌症疗法：克服免疫检查点抑制剂疗法耐药性的策略
Cancers (Basel). 2025 Mar 4;17(5):880. doi: 10.3390/cancers17050880.
6
Coley's Toxin to First Approved Therapeutic Vaccine-A Brief Historical Account in the Progression of Immunobiology-Based Cancer Treatment.科利毒素到首个获批的治疗性疫苗——基于免疫生物学的癌症治疗进展简史
Biomedicines. 2024 Nov 30;12(12):2746. doi: 10.3390/biomedicines12122746.
7
Monoclonal antibodies: From magic bullet to precision weapon.单克隆抗体：从“魔弹”到“精准武器”。
Mol Biomed. 2024 Oct 11;5(1):47. doi: 10.1186/s43556-024-00210-1.
8
Novel therapeutic agents in clinical trials: emerging approaches in cancer therapy.临床试验中的新型治疗药物：癌症治疗的新兴方法。
Discov Oncol. 2024 Aug 11;15(1):342. doi: 10.1007/s12672-024-01195-7.
9
HER2-CD3-Fc Bispecific Antibody-Encoding mRNA Delivered by Lipid Nanoparticles Suppresses HER2-Positive Tumor Growth.脂质纳米颗粒递送的编码HER2-CD3-Fc双特异性抗体的信使核糖核酸可抑制HER2阳性肿瘤生长。
Vaccines (Basel). 2024 Jul 21;12(7):808. doi: 10.3390/vaccines12070808.
10
Tailor-Made Polysaccharides for Biomedical Applications.定制用于生物医学应用的多糖。
ACS Appl Bio Mater. 2024 Jul 15;7(7):4193-4230. doi: 10.1021/acsabm.3c01199. Epub 2024 Jul 3.
本文引用的文献
1
Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.依匹木单抗联合前列腺特异性抗原靶向的痘病毒疫苗治疗转移性去势抵抗性前列腺癌：一项 I 期剂量爬坡试验。
Lancet Oncol. 2012 May;13(5):501-8. doi: 10.1016/S1470-2045(12)70006-2. Epub 2012 Feb 10.
2
Antibodies in oncology.肿瘤学中的抗体。
N Biotechnol. 2011 Sep;28(5):518-29. doi: 10.1016/j.nbt.2011.03.021. Epub 2011 Apr 5.
3
CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans.CD40 激动剂可改变肿瘤基质，并在小鼠和人类中显示出对胰腺癌的疗效。
Science. 2011 Mar 25;331(6024):1612-6. doi: 10.1126/science.1198443.
4
Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas.本妥昔单抗维迪昔（SGN-35）治疗复发性 CD30 阳性淋巴瘤。
N Engl J Med. 2010 Nov 4;363(19):1812-21. doi: 10.1056/NEJMoa1002965.
5
Translating cancer research into targeted therapeutics.将癌症研究转化为靶向治疗。
Nature. 2010 Sep 30;467(7315):543-9. doi: 10.1038/nature09339.
6
Development trends for human monoclonal antibody therapeutics.人源化单克隆抗体治疗药物的发展趋势。
Nat Rev Drug Discov. 2010 Oct;9(10):767-74. doi: 10.1038/nrd3229. Epub 2010 Sep 3.
7
Antibody-drug conjugates for cancer: poised to deliver?用于癌症治疗的抗体药物偶联物：即将发挥作用？
Nat Rev Drug Discov. 2010 Sep;9(9):665-7. doi: 10.1038/nrd3270.
8
Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape.肿瘤抗原靶向的、基于单克隆抗体的免疫治疗：临床反应、细胞免疫和免疫逃逸。
J Clin Oncol. 2010 Oct 1;28(28):4390-9. doi: 10.1200/JCO.2009.27.6360. Epub 2010 Aug 9.
9
Improved survival with ipilimumab in patients with metastatic melanoma.Ipilimumab 改善转移性黑色素瘤患者的生存。
N Engl J Med. 2010 Aug 19;363(8):711-23. doi: 10.1056/NEJMoa1003466. Epub 2010 Jun 5.
10
Dalotuzumab, a recombinant humanized mAb targeted against IGFR1 for the treatment of cancer.达洛珠单抗，一种靶向胰岛素样生长因子受体1（IGFR1）用于治疗癌症的重组人源化单克隆抗体。
Curr Opin Mol Ther. 2010 Jun;12(3):361-71.
Zotero 插件